SG10202008909VA - Prodrugs of cytotoxic active agents having enzymatically cleavable groups - Google Patents

Prodrugs of cytotoxic active agents having enzymatically cleavable groups

Info

Publication number: SG10202008909VA
Authority: SG; Singapore
Prior art keywords: prodrugs; active agents; cleavable groups; enzymatically cleavable; cytotoxic active
Prior art date: 2016-03-24

Sarah Anna Liesa Johannes

Beatrix Stelte-Ludwig

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

Family has litigation

First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=58361030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10202008909V(A)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-03-21Application filed by Bayer Pharma AGfiledCriticalBayer Pharma AG

2020-10-29Publication of SG10202008909VApublicationCriticalpatent/SG10202008909VA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6805—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a vinca alkaloid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

SG10202008909VA2016-03-242017-03-21Prodrugs of cytotoxic active agents having enzymatically cleavable groupsSG10202008909VA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP16162400		2016-03-24
EP16205988		2016-12-21

Publications (1)

Publication Number	Publication Date
SG10202008909VAtrue SG10202008909VA (en)	2020-10-29

Family

ID=58361030

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10202008909VASG10202008909VA (en)	2016-03-24	2017-03-21	Prodrugs of cytotoxic active agents having enzymatically cleavable groups
SG11201808167VASG11201808167VA (en)	2016-03-24	2017-03-21	Prodrugs of cytotoxic active agents having enzymatically cleavable groups

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG11201808167VASG11201808167VA (en)	2016-03-24	2017-03-21	Prodrugs of cytotoxic active agents having enzymatically cleavable groups

Country Status (18)

Country	Link
US (2)	US11685714B2 (en)
EP (1)	EP3432934B1 (en)
JP (1)	JP7251981B2 (en)
KR (1)	KR20180123047A (en)
CN (2)	CN116059390A (en)
AU (1)	AU2017236431A1 (en)
BR (1)	BR112018069483A2 (en)
CA (1)	CA3018630A1 (en)
CL (1)	CL2018002699A1 (en)
CO (1)	CO2018010026A2 (en)
IL (1)	IL261758A (en)
MX (1)	MX2018011627A (en)
PE (1)	PE20181852A1 (en)
RU (1)	RU2018136778A (en)
SG (2)	SG10202008909VA (en)
TW (1)	TW201735954A (en)
UY (1)	UY37168A (en)
WO (1)	WO2017162663A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN114917361A (en)	2015-06-22	2022-08-19	拜耳医药股份有限公司	Antibody Drug Conjugates (ADCs) and Antibody Prodrug Conjugates (APDCs) with Enzymatic Cleavable Groups
CN107921146A (en)	2015-06-23	2018-04-17	拜耳医药股份有限公司	Spindle drives the antibody drug conjugate (ADC) of albumen (KSP) inhibitor and the antibody of anti-CD123
AU2016282724A1 (en)	2015-06-23	2018-01-18	Bayer Pharma Aktiengesellschaft	Targeted conjugates of KSP inhibitors
US11685714B2 (en)	2016-03-24	2023-06-27	Bayer Pharma Aktiengesellschaft	Prodrugs of cytotoxic active agents having enzymatically cleavable groups
EP3471776B1 (en)	2016-06-15	2022-05-04	Bayer Pharma Aktiengesellschaft	Specific antibody-drug-conjugates with ksp inhibitors and anti-cd123-antibodies
CA3047491A1 (en)*	2016-12-21	2018-06-28	Bayer Aktiengesellschaft	Prodrugs of cytotoxic active agents having enzymatically cleavable groups
IL310558A (en)*	2016-12-21	2024-03-01	Bayer Pharma AG	Antibody drug conjugates (adcs) having enzymatically cleavable groups
US11433140B2 (en)	2016-12-21	2022-09-06	Bayer Pharma Aktiengesellschaft	Specific antibody drug conjugates (ADCs) having KSP inhibitors
US20240024495A1 (en)*	2017-07-10	2024-01-25	Sri International	A peptide saporin conjugate for the treatment of cancer
JP7368856B2 (en)	2017-07-25	2023-10-25	トゥルーバインディング，インコーポレイテッド	Cancer treatment by blocking the interaction between TIM-3 and its ligand
CA3103327A1 (en)*	2018-06-18	2019-12-26	Bayer Aktiengesellschaft	Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile
AU2019387370A1 (en)	2018-11-30	2021-06-10	Nuvation Bio Inc.	Pyrrole and pyrazole compounds and methods of use thereof
SG11202106520VA (en)	2018-12-20	2021-07-29	Amgen Inc	Kif18a inhibitors
CN110428870B (en)*	2019-08-08	2023-03-21	苏州泓迅生物科技股份有限公司	Method for predicting antibody heavy chain and light chain pairing probability and application thereof
CN116157151A (en)	2020-05-26	2023-05-23	真和制药有限公司	Methods of treating inflammatory diseases by blocking galectin-3
CN113754541B (en)*	2020-06-02	2025-01-03	深圳湾实验室	Small molecule inhibitor targeting Epstein-Barr virus nuclear antigen protein, preparation method and application thereof
WO2022167052A1 (en)*	2021-02-08	2022-08-11	Y-Mabs Therapeutics, Inc.	Use of ascorbic acid as stabilizing agent for anti b7-h3 antibodies
KR20230145332A (en)*	2021-02-16	2023-10-17	글리코스 핀란드 오이	Linker-payload and conjugates thereof
CN112979491B (en)*	2021-02-24	2022-04-15	中国药科大学	A compound containing hydrogen peroxide/cathepsin L responsive protecting group and application thereof
IL310863A (en)	2021-08-26	2024-04-01	Volastra Therapeutics Inc	KIF18A inhibitors in the spiro indoline form
TW202434289A (en)	2022-11-17	2024-09-01	德商拜耳廠股份有限公司	Antibody-drug conjugates (a2dcs) with enzymatically cleavable groups
WO2024229406A1 (en)	2023-05-04	2024-11-07	Revolution Medicines, Inc.	Combination therapy for a ras related disease or disorder
WO2025034702A1 (en)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Rmc-6291 for use in the treatment of ras protein-related disease or disorder
US20250154171A1 (en)	2023-10-12	2025-05-15	Revolution Medicines, Inc.	Ras inhibitors

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4714681A (en)	1981-07-01	1987-12-22	The Board Of Reagents, The University Of Texas System Cancer Center	Quadroma cells and trioma cells and methods for the production of same
US4474893A (en)	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies
US4510245A (en)	1982-11-18	1985-04-09	Chiron Corporation	Adenovirus promoter system
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
DE8808645U1 (en)	1988-07-06	1988-08-25	Hofer, Daniel, 7730 Villingen-Schwenningen	Display device for fire extinguishers
US4925648A (en)	1988-07-29	1990-05-15	Immunomedics, Inc.	Detection and treatment of infectious and inflammatory lesions
US5601819A (en)	1988-08-11	1997-02-11	The General Hospital Corporation	Bispecific antibodies for selective immune regulation and for selective immune cell binding
DE69029036T2 (en)	1989-06-29	1997-05-22	Medarex Inc	SPECIFIC REAGENTS FOR AIDS THERAPY
WO1991005871A1 (en)	1989-10-20	1991-05-02	Medarex, Inc.	Bispecific heteroantibodies with dual effector functions
US5270163A (en)	1990-06-11	1993-12-14	University Research Corporation	Methods for identifying nucleic acid ligands
WO1992005793A1 (en)	1990-10-05	1992-04-16	Medarex, Inc.	Targeted immunostimulation with bispecific reagents
DE69128253T2 (en)	1990-10-29	1998-06-18	Chiron Corp	SPECIFIC ANTIBODIES, METHOD FOR THEIR PRODUCTION AND THEIR USE
WO1992015683A1 (en)	1991-03-06	1992-09-17	MERCK Patent Gesellschaft mit beschränkter Haftung	Humanized and chimeric monoclonal antibodies
ATE144624T1 (en)	1991-04-26	1996-11-15	Surface Active Ltd	NEW ANTIBODIES AND METHODS OF USE THEREOF
EP1306095A3 (en)	1992-03-05	2003-06-25	Board Of Regents, The University Of Texas System	Methods and compositions for targeting the vasculature of solid tumors
DK0719859T3 (en)	1994-12-20	2003-10-20	Merck Patent Gmbh	Anti-alpha V integrin monoclonal antibody
ES2176484T3 (en)	1995-08-18	2002-12-01	Morphosys Ag	PROTEIN BANKS / (POLI) PEPTIDES.
US6177078B1 (en)	1995-12-29	2001-01-23	Medvet Science Pty Limited	Monoclonal antibody antagonists to IL-3
US6150508A (en)	1996-03-25	2000-11-21	Northwest Biotherapeutics, Inc.	Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
WO1997035616A1 (en)	1996-03-25	1997-10-02	Pacific Northwest Cancer Foundation	Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen
NZ517331A (en)	1999-07-29	2004-02-27	Medarex Inc	Human monoclonal antibodies to prostate specific membrane antigen and a transgenic mouse to produce the antibody
WO2001062931A2 (en)	2000-02-25	2001-08-30	The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services	ANTI-EGFRvIII SCFVS WITH IMPROVED CYTOTOXICITY AND YIELD, IMMUNOTOXINS BASED THEREON, AND METHODS OF USE THEREOF
WO2001088138A1 (en)	2000-05-19	2001-11-22	Scancell Limited	Humanised antibodies to the epidermal growth factor receptor
US7288390B2 (en)	2000-08-07	2007-10-30	Centocor, Inc.	Anti-dual integrin antibodies, compositions, methods and uses
AUPR395801A0 (en)	2001-03-26	2001-04-26	Austin Research Institute, The	Antibodies against cancer
GEP20074091B (en)	2001-04-26	2007-04-25	Biogen Idec Inc	Cripto blocking antibodies and uses thereof
AU2002334799B2 (en)	2001-04-26	2009-05-07	Biogen Ma Inc.	Cripto-specific antibodies
EP2335728A1 (en)	2001-05-11	2011-06-22	Ludwig Institute for Cancer Research Ltd.	Specific binding proteins and uses thereof
WO2002100348A2 (en)	2001-06-13	2002-12-19	Genmab A/S	Human monoclonal antibodies to epidermal growth factor receptor (egfr)
US7595378B2 (en)	2001-06-13	2009-09-29	Genmab A/S	Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
ES2606537T3 (en)	2001-10-23	2017-03-24	Psma Development Company L.L.C.	Antibodies against PSMA
PL216223B1 (en)	2002-03-13	2014-03-31	Biogen Idec Inc	Anti-alpha v beta 6 antibodies
EP1519958B1 (en)	2002-06-14	2014-10-15	Immunomedics, Inc.	Humanized monoclonal antibody hpam4
WO2004091375A2 (en)	2003-04-11	2004-10-28	Medimmune, Inc.	Epha2 and non-neoplastic hyperproliferative cell disorders
CN104119439A (en)	2003-06-27	2014-10-29	艾默根佛蒙特有限公司	Antibodies directed to deletion mutants of epidermal growth factor receptor and uses thereof
KR101263950B1 (en)	2003-07-21	2013-05-31	이뮤노젠 아이엔씨	6 a ca6 antigen-specific cytotoxic conjugate and methods of using the same
PT1725249E (en)	2003-11-06	2014-04-10	Seattle Genetics Inc	Monomethylvaline compounds capable of conjugation to ligands
EP1701979A2 (en)	2003-12-03	2006-09-20	Xencor, Inc.	Optimized antibodies that target the epidermal growth factor receptor
US7767792B2 (en)	2004-02-20	2010-08-03	Ludwig Institute For Cancer Research Ltd.	Antibodies to EGF receptor epitope peptides
JP4734319B2 (en)	2004-03-19	2011-07-27	イムクローン・リミテッド・ライアビリティ・カンパニー	Human anti-epidermal growth factor receptor antibody
JP5130044B2 (en)	2004-08-03	2013-01-30	イナート・ファルマ	Therapeutic and diagnostic methods and compositions targeting 4IG-B7-H3 and its corresponding NK cell receptor
UA94388C2 (en)	2004-12-09	2011-05-10	Центокор, Инк.	Anti-integrin immunoconjugate and treatment method using thereof
ATE462726T1 (en)	2005-01-07	2010-04-15	Diadexus Inc	OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF
ES2498794T3 (en)	2005-02-18	2014-09-25	Medarex, L.L.C.	Monoclonal antibodies against CD30 that lack fucosyl moieties
PL1912677T3 (en)	2005-06-20	2014-03-31	Psma Dev Company L L C	PSMA antibody-drug conjugates
RS52470B (en)	2005-08-24	2013-02-28	Immunogen Inc.	Process for preparing maytansinoid antibody conjugates
NZ566395A (en)	2005-09-26	2012-03-30	Medarex Inc	Human monoclonal antibodies to CD70
DOP2006000277A (en)	2005-12-12	2007-08-31	Bayer Pharmaceuticals Corp	ANTI MN ANTIBODIES AND METHODS FOR USE
WO2008004834A1 (en)	2006-07-06	2008-01-10	Isu Abxis Co., Ltd	Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor
AU2007294575B2 (en)	2006-09-08	2013-06-27	Viela Bio, Inc.	Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US9051356B2 (en)	2006-09-10	2015-06-09	Glycotope Gmbh	Use of human cells of myeloid leukaemia origin for expression of antibodies
EP1900750A1 (en)	2006-09-18	2008-03-19	Glycotope Gmbh	Fully human high yield production system for improved antibodies
EP1911766A1 (en)	2006-10-13	2008-04-16	Glycotope Gmbh	Use of human cells of myeloid leukaemia origin for expression of antibodies
US8394374B2 (en)	2006-09-18	2013-03-12	Xencor, Inc.	Optimized antibodies that target HM1.24
EP1914242A1 (en)	2006-10-19	2008-04-23	Sanofi-Aventis	Novel anti-CD38 antibodies for the treatment of cancer
EP2099823B2 (en)	2006-12-01	2022-02-09	Seagen Inc.	Variant target binding agents and uses thereof
WO2008140603A2 (en)	2006-12-08	2008-11-20	Macrogenics, Inc.	METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
WO2008092117A2 (en)	2007-01-25	2008-07-31	Xencor, Inc.	Immunoglobulins with modifications in the fcr binding region
JP2010523478A (en)	2007-03-22	2010-07-15	スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ	Use of monoclonal antibody 8H9
NZ556142A (en)	2007-06-25	2009-11-27	Novartis Ag	Animal remedy dispensing means
BRPI0814768A2 (en)	2007-08-03	2015-03-03	Facet Biotech Corp	THERAPEUTIC USE OF ANTI-TWEAK RECEPTOR ANTIBODIES
CA2696360C (en)	2007-08-14	2018-11-20	Ludwig Institute For Cancer Research	Monoclonal antibody targeting the egfr receptor and uses thereof
EP2185188B1 (en)	2007-08-22	2014-08-06	Medarex, L.L.C.	Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
CA2698203C (en)	2007-08-29	2018-09-11	Sanofi-Aventis	Humanized anti-cxcr5 antibodies, derivatives thereof and their use
US8039597B2 (en)	2007-09-07	2011-10-18	Agensys, Inc.	Antibodies and related molecules that bind to 24P4C12 proteins
EP2185574B1 (en)	2007-09-07	2013-05-08	Agensys, Inc.	Antibodies and related molecules that bind to 24p4c12 proteins
HUE027358T2 (en)	2007-11-26	2016-09-28	Bayer Ip Gmbh	Anti-mesothelin antibodies and uses therefor
WO2009070844A1 (en)	2007-12-06	2009-06-11	Csl Limited	Method of inhibition of leukemic stem cells
MX2010007102A (en)	2007-12-26	2011-07-01	Biotest Ag	Immunoconjugates targeting cd138 and uses thereof.
KR101626416B1 (en)	2007-12-26	2016-06-01	바이오테스트 아게	Agents targeting cd138 and uses thereof
JP5555223B2 (en)	2008-04-02	2014-07-23	マクロジェニクス，インコーポレーテッド	HER2 / neu specific antibody and method of use thereof
WO2009140177A2 (en)	2008-05-15	2009-11-19	Biogen Idec Ma Inc.	Anti-fn14 antibodies and uses thereof
AU2009287163B2 (en)	2008-08-29	2014-11-13	Les Laboratoires Servier	Recombinant anti-Epidermal Growth Factor Receptor antibody compositions
AR075982A1 (en)	2009-03-31	2011-05-11	Roche Glycart Ag	COMBINATION THERAPY OF A AFUCOSILATED ANTIBODY AND ONE OR MORE OF THE SELECTED CYTOKINS OF GM-CSF HUMAN, M-CSF HUMAN AND / OR IL-3 HUMAN AND COMPOSITION
JP2012518680A (en)	2009-03-31	2012-08-16	ロシュグリクアートアクチェンゲゼルシャフト	Treatment of cancer with humanized anti-EGFR IgG1 antibody and irinotecan
WO2010126066A1 (en)	2009-04-27	2010-11-04	協和発酵キリン株式会社	Anti-il-3rα antibody for use in treatment of blood tumor
CN101959216B (en)	2009-07-20	2014-06-18	电信科学技术研究院	Method, system and device for enhancing CELL_FACH (Cell Forward Access Channel) by carrier wave configuration
WO2011044368A1 (en)	2009-10-07	2011-04-14	Macrogenics, Inc.	Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
MX2012010966A (en)	2010-03-22	2013-01-29	Lead Discovery Center Gmbh	Pharmaceutically active disubstituted triazine derivatives.
NZ604510A (en)	2010-08-17	2013-10-25	Csl Ltd	Dilutable biocidal compositions and methods of use
WO2012112363A1 (en)	2011-02-14	2012-08-23	Merck Sharp & Dohme Corp.	Cathepsin cysteine protease inhibitors
CN106117312A (en)	2011-04-21	2016-11-16	西雅图基因公司	New bonding agent drug conjugate (ADC) and application thereof
AR088941A1 (en)	2011-11-23	2014-07-16	Bayer Ip Gmbh	ANTI-FGFR2 ANTIBODIES AND THEIR USES
WO2013092983A2 (en)	2011-12-23	2013-06-27	Innate Pharma	Enzymatic conjugation of polypeptides
EP2850106B1 (en)	2012-05-18	2022-03-23	Aptevo Research and Development LLC	Bispecific scfv immunofusion (bif) binding to cd123 and cd3
WO2014062697A2 (en)*	2012-10-16	2014-04-24	Endocyte, Inc.	Drug delivery conjugates containing unnatural amino acids and methods for using
WO2014061277A1 (en)	2012-10-19	2014-04-24	第一三共株式会社	Antibody-drug conjugate produced by binding through linker having hydrophilic structure
WO2014151030A1 (en)	2013-03-15	2014-09-25	Novartis Ag	Cell proliferation inhibitors and conjugates thereof
KR20160019434A (en)	2013-06-14	2016-02-19	바이엘 파마 악티엔게젤샤프트	Anti-tweakr antibodies and uses thereof
NZ720736A (en)	2013-12-23	2020-08-28	Bayer Pharma AG	Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
JP6539729B2 (en)	2014-06-03	2019-07-03	ジアリー・ファーマシューティカルズ・インコーポレイテッドＪｉａｒａｙＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Peptide-drug complex
WO2015189143A1 (en)	2014-06-12	2015-12-17	Bayer Pharma Aktiengesellschaft	Aglycosyl anti-tweakr antibodies and uses thereof
JP6743015B2 (en)	2014-12-15	2020-08-19	バイエルファーマアクチエンゲゼルシャフト	Antibody drug conjugates (ADCs) with deglycosylated anti-TWEAKR antibody of KSP inhibitor
CN114917361A (en)*	2015-06-22	2022-08-19	拜耳医药股份有限公司	Antibody Drug Conjugates (ADCs) and Antibody Prodrug Conjugates (APDCs) with Enzymatic Cleavable Groups
CN107921146A (en)	2015-06-23	2018-04-17	拜耳医药股份有限公司	Spindle drives the antibody drug conjugate (ADC) of albumen (KSP) inhibitor and the antibody of anti-CD123
JP6905941B2 (en)	2015-06-23	2021-07-21	バイエルファーマアクチエンゲゼルシャフト	Antibody drug conjugate with anti-B7H3 antibody of kinesin spindle protein (KSP) inhibitor
AU2016282724A1 (en)	2015-06-23	2018-01-18	Bayer Pharma Aktiengesellschaft	Targeted conjugates of KSP inhibitors
US11685714B2 (en)	2016-03-24	2023-06-27	Bayer Pharma Aktiengesellschaft	Prodrugs of cytotoxic active agents having enzymatically cleavable groups
EP3471776B1 (en)	2016-06-15	2022-05-04	Bayer Pharma Aktiengesellschaft	Specific antibody-drug-conjugates with ksp inhibitors and anti-cd123-antibodies
US11433140B2 (en)	2016-12-21	2022-09-06	Bayer Pharma Aktiengesellschaft	Specific antibody drug conjugates (ADCs) having KSP inhibitors
CA3047491A1 (en)	2016-12-21	2018-06-28	Bayer Aktiengesellschaft	Prodrugs of cytotoxic active agents having enzymatically cleavable groups
IL310558A (en)	2016-12-21	2024-03-01	Bayer Pharma AG	Antibody drug conjugates (adcs) having enzymatically cleavable groups
CA3103327A1 (en)	2018-06-18	2019-12-26	Bayer Aktiengesellschaft	Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile

2017
- 2017-03-21USUS16/087,928patent/US11685714B2/enactiveActive
- 2017-03-21MXMX2018011627Apatent/MX2018011627A/enunknown
- 2017-03-21JPJP2018549445Apatent/JP7251981B2/enactiveActive
- 2017-03-21RURU2018136778Apatent/RU2018136778A/ennot_activeApplication Discontinuation
- 2017-03-21PEPE2018001862Apatent/PE20181852A1/ennot_activeApplication Discontinuation
- 2017-03-21KRKR1020187027099Apatent/KR20180123047A/ennot_activeCeased
- 2017-03-21CNCN202211097986.XApatent/CN116059390A/enactivePending
- 2017-03-21CACA3018630Apatent/CA3018630A1/enactivePending
- 2017-03-21CNCN201780019957.2Apatent/CN108883195A/enactivePending
- 2017-03-21WOPCT/EP2017/056684patent/WO2017162663A1/enactiveApplication Filing
- 2017-03-21SGSG10202008909VApatent/SG10202008909VA/enunknown
- 2017-03-21EPEP17712140.7Apatent/EP3432934B1/enactiveActive
- 2017-03-21BRBR112018069483Apatent/BR112018069483A2/ennot_activeApplication Discontinuation
- 2017-03-21AUAU2017236431Apatent/AU2017236431A1/ennot_activeAbandoned
- 2017-03-21SGSG11201808167VApatent/SG11201808167VA/enunknown
- 2017-03-24TWTW106109896Apatent/TW201735954A/enunknown
- 2017-03-24UYUY0001037168Apatent/UY37168A/ennot_activeApplication Discontinuation
2018
- 2018-09-13ILIL261758Apatent/IL261758A/enunknown
- 2018-09-24CLCL2018002699Apatent/CL2018002699A1/enunknown
- 2018-09-24COCONC2018/0010026Apatent/CO2018010026A2/enunknown
2023
- 2023-02-27USUS18/175,265patent/US20240043379A1/enactivePending

Also Published As

Publication number	Publication date
EP3432934A1 (en)	2019-01-30
JP2019512517A (en)	2019-05-16
CL2018002699A1 (en)	2019-01-18
BR112018069483A2 (en)	2019-07-30
US20190077752A1 (en)	2019-03-14
WO2017162663A1 (en)	2017-09-28
CN108883195A (en)	2018-11-23
PE20181852A1 (en)	2018-12-03
AU2017236431A1 (en)	2018-09-27
US11685714B2 (en)	2023-06-27
SG11201808167VA (en)	2018-10-30
UY37168A (en)	2017-10-31
CN116059390A (en)	2023-05-05
MX2018011627A (en)	2019-01-10
IL261758A (en)	2018-10-31
AU2017236431A2 (en)	2018-11-08
RU2018136778A (en)	2020-04-24
CO2018010026A2 (en)	2018-09-28
KR20180123047A (en)	2018-11-14
TW201735954A (en)	2017-10-16
JP7251981B2 (en)	2023-04-04
CA3018630A1 (en)	2017-09-28
EP3432934B1 (en)	2022-02-23
US20240043379A1 (en)	2024-02-08

Publication	Publication Date	Title
IL261758A (en)	2018-10-31	Prodrugs of cytotoxic active agents having enzymatically cleavable groups
ECSP18090743A (en)	2019-01-31	SUBSTITUTE CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTINEOPLASTIC AGENTS
ZA201800395B (en)	2021-07-28	Binder-drug conjugates (adcs) and binder-prodrug conjugates (apdcs) having enzymatically cleavable groups
EP3193828B8 (en)	2023-04-05	Microstructure array for delivery of active agents
IL262419A (en)	2018-12-31	Cannabis-enriched enzymatically treated therapeutic composition
GB201714115D0 (en)	2017-10-18	Cytotoxic agents
EP3116492A4 (en)	2017-11-08	Pharmaceutical compositions of therapeutically active compounds
ZA201800449B (en)	2019-07-31	Targeted conjugates of ksp inhibitors
IL252153A0 (en)	2017-07-31	Prodrugs of tizoxamide, analogues and salts thereof, compositions comprising same and uses thereof
IL275534A (en)	2020-08-31	Lysophosphatidylcholine compositions
SI3116491T1 (en)	2021-12-31	Pharmaceutical compositions of therapeutically active compounds
PL3464309T3 (en)	2020-10-19	Phosphoramidate nucleoside derivatives as anticancer agents
IL265856A (en)	2019-06-30	Formulations for administration of eflornithine
IL260008A (en)	2018-07-31	Formulations of phosphoramidate derivatives of nucleoside drugs
EP3405151A4 (en)	2019-09-11	Enhanced transdermal delivery of active agents
EP3324958A4 (en)	2018-10-24	Salts and prodrugs of 1-methyl-d-tryptophan
IL263993A (en)	2019-02-28	Phosphorus prodrugs of sgc stimulators
EP3104857A4 (en)	2017-10-11	Cyclic peroxides as prodrugs for selective delivery of agents
EP3094314A4 (en)	2017-08-16	Targeted nanocarriers for the administration of immunosuppressive agents
EP3223858A4 (en)	2018-07-11	Tlr9 targeted cytotoxic agents
EP3313380A4 (en)	2019-03-20	Composition for delivery of active agents to an animal
IL256486A (en)	2018-02-28	Formulations for improving the efficacy of hydrophobic drugs
EP3506947A4 (en)	2020-06-03	Pharmaceutical formulations of regadenoson
HK1258512A1 (en)	2019-11-15	Prodrugs of fencamfamine
HK40092207A (en)	2023-12-22	Prodrugs of cytotoxic active agents having enzymatically cleavable groups

Movatterモバイル変換